🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Agilent Technologies, Inc. A SPXR3KPHARMA

Healthcare · Diagnostics & Research · United States
https://www.agilent.com
Company Profile ↓
$173.07
+45.03% 1Y
Mkt Cap$48.79B
P/E34.14
P/B6.53
Div. Yield0.61%
52W High$177.75
52W Low$109.61
Book Value$26.11
EPS (TTM)$5.07

Company Overview

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 21.0%, reflecting efficient use of shareholder capital.

Healthy Margins

Maintains a net profit margin of 19.5%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Oct 2025 Revenue of $6.95B (+6.7% YoY); net profit $1.30B.
  • Trailing 12 Months Year-on-year growth — revenue +8.1%, earnings +8.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 0.5%, profit CAGR 1.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:0.48%
1 Year:8.10%

Compounded Profit Growth

5 Years:1.29%
1 Year:8.50%

Stock Price Performance

1 Year:+45.03%
6 Months:+50.29%
3 Months:+25.70%
1 Month:+0.28%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 93% of range
$109.61 $177.75
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)57.41 · Neutral
Price Performance
1M+0.28%
3M+25.70%
6M+50.29%
1Y+45.03%
Valuation vs Sector

P/E of 34.14 is above the sector median of 25.45 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 21.0%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
34.14
Industry PE
25.45
Forward P/E
25.61
PEG Ratio
1.40
Book Value
$26.11
Price to Book
6.53
P/S
6.52
EV/EBITDA
24.07
Dividend Yield
0.61%

Growth (CAGR)

Revenue 5Y
0.48%
Profit 5Y
1.29%
Revenue (YoY)
8.10%
Earnings (YoY)
8.50%

Profitability & Returns

ROCE
14.90%
ROE
20.97%
ROA
8.63%
Profit Margin
19.53%
Op Margin
25.56%
Gross Margin
53.65%
EPS (Latest Qtr)
$1.20
EPS (TTM)
$5.07

Balance Sheet & Liquidity

Debt/Equity
0.56
Quick Ratio
1.41
Current Ratio
2.05
Debt
$4.15B
Total Assets
$13.06B
Current Assets
$4.76B
Working Capital
$2.25B

Ownership

Promoter Holding
0.19%
Chg in Prom Hold
-0.00%
FII / Inst Holding
95.42%
Chg in FII Hold
-0.08%

Financial Snapshot

Enterprise Value
$48.79B
Total Revenue (TTM)
$7.37B
EBITDA
$2.08B
Free Cash Flow
$1.06B
Operating Cash Flow
$1.61B
Shares Outstanding
281.93M
Gross Margin
53.65%
Payout Ratio
19.98%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 A Agilent Technologies, Inc. SPXR3KPHARMA 173.07 34.14 $48.79B 0.61% 14.90% 20.97% 0.48% 1.29%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jul 2013Jan 2014Apr 2014Jul 2014Jan 2015Apr 2015Jul 2015Jan 2016Apr 2016Jul 2016Jan 2017Apr 2017Jul 2017Jan 2018Apr 2018Jul 2018Jan 2019Apr 2019Jul 2019Jan 2020Apr 2020Jul 2020Jan 2021Apr 2021Jul 2021Jan 2022Apr 2022Jul 2022Jan 2023Apr 2023Jul 2023Jan 2024Apr 2024Jul 2024Jan 2025Apr 2025Jul 2025Oct 2025Jan 2026Apr 2026
Revenue ------------1.11B1.21B1.21B1.20B1.28B1.24B1.27B1.36B1.24B1.26B1.55B1.52B1.59B1.67B1.61B1.72B1.76B1.72B1.67B1.66B1.57B1.58B1.68B1.67B1.74B1.86B1.80B1.83B
Cost of Revenue -----------------------------------802.00M850.00M871.00M852.00M845.00M
Gross Profit -----------------------------------866.00M888.00M990.00M946.00M990.00M
Operating Expenses -----------------------------------566.00M528.00M547.00M593.00M591.00M
Operating Income 236.00M124.00M94.00M131.00M115.00M107.00M144.00M155.00M131.00M146.00M206.00M201.00M201.00M229.00M210.00M221.00M250.00M216.00M225.00M215.00M102.00M230.00M328.00M288.00M336.00M376.00M360.00M411.00M426.00M383.00M133.00M384.00M363.00M333.00M376.00M300.00M360.00M443.00M353.00M399.00M
EBITDA -----------------------------------362.00M466.00M540.00M456.00M500.00M
Interest Expense -----------------------------------29.00M28.00M27.00M25.00M25.00M
Pretax Income -----------------------------------260.00M366.00M442.00M364.00M408.00M
Tax Provision -----------------------------------45.00M30.00M8.00M59.00M69.00M
Net Income -------121.00M91.00M124.00M168.00M164.00M175.00M-320.00M205.00M236.00M504.00M182.00M191.00M197.00M101.00M199.00M288.00M216.00M264.00M283.00M274.00M329.00M352.00M302.00M111.00M348.00M308.00M282.00M318.00M215.00M336.00M434.00M305.00M339.00M
Diluted EPS 0.490.580.410.430.190.260.330.360.280.380.520.500.54-0.990.630.731.570.570.600.630.320.640.930.700.860.930.911.101.191.020.381.181.050.971.110.751.181.531.071.20
R&D Expense 171.00M88.00M87.00M86.00M88.00M81.00M79.00M78.00M81.00M86.00M79.00M84.00M87.00M94.00M92.00M97.00M102.00M99.00M101.00M104.00M197.00M92.00M103.00M109.00M113.00M117.00M115.00M116.00M123.00M126.00M118.00M128.00M113.00M127.00M113.00M112.00M111.00M-117.00M126.00M

Profit & Loss (Annual)

Figures in USD.

Metric Oct 2007Oct 2008Oct 2009Oct 2010Oct 2011Oct 2012Oct 2013Oct 2014Oct 2015Oct 2016Oct 2017Oct 2018Oct 2019Oct 2020Oct 2021Oct 2022Oct 2023Oct 2024Oct 2025
Revenue 5.42B5.77B4.48B5.44B6.62B6.86B3.89B4.05B4.04B4.20B4.47B4.91B5.16B5.34B6.32B6.85B6.83B6.51B6.95B
Cost of Revenue ---------------3.13B3.37B2.98B3.31B
Gross Profit ---------------3.72B3.46B3.54B3.64B
Operating Expenses ---------------2.10B2.12B2.05B2.16B
Operating Income 584.00M795.00M47.00M566.00M1.07B1.12B386.00M419.00M522.00M615.00M807.00M904.00M941.00M846.00M1.35B1.62B1.35B1.49B1.48B
EBITDA ---------------1.91B1.71B1.87B1.83B
Interest Expense ---------------84.00M95.00M96.00M112.00M
Pretax Income ---------------1.50B1.34B1.52B1.44B
Tax Provision ---------------250.00M99.00M232.00M132.00M
Net Income -------------719.00M1.21B1.25B1.24B1.29B1.30B
Diluted EPS 1.571.87-0.091.942.853.272.131.621.201.402.100.973.372.303.944.184.194.434.57
R&D Expense 685.00M704.00M642.00M612.00M649.00M668.00M337.00M358.00M330.00M329.00M341.00M387.00M404.00M495.00M441.00M467.00M481.00M479.00M455.00M

Balance Sheet (Annual)

Figures in USD.

Metric Oct 2006Oct 2007Oct 2008Oct 2009Oct 2010Oct 2011Oct 2012Oct 2013Oct 2014Oct 2015Oct 2016Oct 2017Oct 2018Nov 2018Oct 2019Oct 2020Oct 2021Oct 2022Oct 2023Oct 2024Oct 2025
Total Assets --7.01B7.61B9.70B9.06B10.54B10.69B10.81B7.48B7.79B8.43B8.54B8.56B9.45B9.63B-10.53B10.76B11.85B12.73B
Current Assets -----------------3.78B4.19B3.96B4.59B
Cash & Equivalents 2.26B1.83B1.41B2.48B2.65B3.53B2.35B2.67B2.22B2.00B2.29B2.68B2.25B2.25B1.38B1.44B-1.05B1.59B1.33B1.79B
Inventory -----------------1.04B1.03B972.00M1.02B
Receivables -----------------1.41B1.29B1.32B1.49B
Total Liabilities --4.45B5.10B6.46B4.74B5.35B5.40B5.51B3.31B3.55B3.59B3.97B3.96B4.70B4.75B-5.23B4.92B5.95B5.99B
Current Liabilities --1.33B1.12B3.08B1.84B1.89B1.60B1.69B976.00M945.00M1.26B1.17B1.16B2.08B1.47B-1.86B1.60B1.90B2.35B
Long Term Debt --1.51B2.90B2.19B1.93B2.11B2.70B1.66B1.66B1.90B1.80B1.80B1.80B1.79B2.28B-2.73B2.73B3.35B3.05B
Total Debt -----------------2.77B2.73B3.39B3.35B
Total Equity 3.65B3.23B2.56B2.51B3.23B4.31B5.18B5.29B5.30B4.17B4.24B4.83B4.57B4.59B4.75B4.87B-5.30B5.84B5.90B6.74B
Shares Outstanding -----------------295.00M292.12M285.19M283.05M

Cash Flows (Annual)

Figures in USD.

Metric Oct 2007Oct 2008Oct 2009Oct 2010Oct 2011Oct 2012Oct 2013Oct 2014Oct 2015Oct 2016Oct 2017Oct 2018Oct 2019Oct 2020Oct 2021Oct 2022Oct 2023Oct 2024Oct 2025
Operating Cash Flow 969.00M756.00M408.00M718.00M1.26B1.23B1.15B731.00M512.00M793.00M889.00M1.09B1.02B921.00M-1.31B1.77B1.75B1.56B
Investing Cash Flow -456.00M-399.00M-14.00M-1.17B1.29B-2.37B-248.00M-230.00M-400.00M-238.00M-304.00M-705.00M-1.59B-147.00M--338.00M-310.00M-1.26B-394.00M
Financing Cash Flow -980.00M-774.00M657.00M601.00M-1.69B-37.00M-554.00M-117.00M-1.09B-268.00M-202.00M-797.00M-299.00M-717.00M--1.37B-930.00M-752.00M-715.00M
Capital Expenditure -154.00M-154.00M-128.00M-121.00M-188.00M-194.00M-195.00M-205.00M-98.00M-139.00M-176.00M-177.00M-155.00M-119.00M--291.00M-298.00M-378.00M-407.00M
Free Cash Flow 815.00M602.00M280.00M597.00M1.07B1.03B957.00M526.00M414.00M654.00M713.00M910.00M866.00M802.00M-1.02B1.47B1.37B1.15B
Net Change in Cash ----------------398.00M532.00M-259.00M450.00M
Share Buybacks 1.94B1.00B157.00M411.00M497.00M172.00M900.00M200.00M267.00M434.00M194.00M422.00M723.00M469.00M788.00M1.14B575.00M1.15B425.00M

Ratios (Annual)

Figures in %.

Metric Oct 2007Oct 2008Oct 2009Oct 2010Oct 2011Oct 2012Oct 2013Oct 2014Oct 2015Oct 2016Oct 2017Oct 2018Oct 2019Oct 2020Oct 2021Oct 2022Oct 2023Oct 2024Oct 2025
Gross Margin % ---------------54.4%50.7%54.3%52.4%
Operating Margin % 10.8%13.8%1.0%10.4%16.2%16.3%9.9%10.4%12.9%14.6%18.0%18.4%18.2%15.8%21.3%23.6%19.8%22.9%21.3%
Net Margin % -------------13.5%19.1%18.3%18.1%19.8%18.8%
ROE % -------------14.8%-23.6%21.2%21.9%19.3%
ROCE % -14.0%0.7%8.6%14.8%12.9%4.2%4.6%8.0%9.0%11.3%12.3%12.8%10.4%-18.7%14.7%15.0%14.2%

Shareholding Pattern

Insiders
0.19%
Institutions
95.42%
Public Float
95.60%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.08% 25.60M $4.37B
2 Vanguard Capital Management LLC 6.54% 18.45M $3.15B
3 Vanguard Portfolio Management LLC 5.12% 14.44M $2.46B
4 State Street Corporation 4.56% 12.85M $2.19B
5 Massachusetts Financial Services Co. 3.55% 10.01M $1.71B
6 T. Rowe Price Investment Management, Inc. 2.75% 7.76M $1.32B
7 Geode Capital Management, LLC 2.69% 7.60M $1.30B
8 Wellington Management Group, LLP 2.64% 7.45M $1.27B
9 Deutsche Bank AG 2.49% 7.01M $1.20B
10 Bank Of New York Mellon Corporation 1.86% 5.23M $892.60M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for A

Yahoo Finance Wed, 14 Oct 2026

Agilent acquires Proscia in deal worth up to $270m

The transaction, which is expected to close in Agilent’s fiscal year 2027, follows its $950m acquisition of Biocare Medical in March 2026.

Yahoo Finance Wed, 14 Oct 2026

Global Metabolomics Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 17.3% CAGR as Thermo Fisher, Bruker, Agilent, and Metabolon Accelerate AI Diagnostics

Players: Metabolon, Bruker, Agilent, Thermo Fisher and Waters. Profiles cover products, services, market share, segments, trends, opportunities and regional presence.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "Metabolomics Market Report 2026…

Yahoo Finance Wed, 14 Oct 2026

Agilent to buy Proscia for $240M

The digital pathology firm “fits in very well” with Agilent and moves the company into a sector targeted by Roche, analysts said.

Yahoo Finance ue, 13 Oct 2026

Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence

SANTA CLARA, Calif. & PHILADELPHIA, October 13, 2026--Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Proscia®, a provider of digital pathology software for clinical and life-science…

Yahoo Finance Mon, 12 Oct 2026

Is Agilent Technologies (A) Outperforming Other Medical Stocks This Year?

Here is how Agilent Technologies (A) and Concentra Group (CON) have performed compared to their sector so far this year.

Yahoo Finance hu, 08 Oct 2026

Is Agilent Technologies (A) Cheap Enough To Justify Its Cash Flow?

Agilent Technologies has delivered a solid share price run over recent years, and the question now is whether the current valuation is properly backed by the cash the business can generate. With fresh investment in new labs and instruments …

A — Frequently Asked Questions

What is the current share price of Agilent Technologies, Inc. (A)?

As of 2026-10-23 16:27 PDT, Agilent Technologies, Inc. (A) trades at $173.07 on NYSE. Its 52-week range is $109.61 to $177.75.

What is the market capitalisation of A?

Agilent Technologies, Inc. (A) has a market capitalisation of $48.79B on NYSE.

What is the P/E ratio of A?

A trades at a trailing price-to-earnings (P/E) ratio of 34.14. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 6.53.

Does A pay a dividend?

Agilent Technologies, Inc. (A) currently offers a dividend yield of 0.61%.

What is the return on equity (ROE) of A?

A has a return on equity (ROE) of 20.97%. Its return on capital employed (ROCE) is 14.90%.

Is A a good stock to buy?

This page provides a data-driven analysis of Agilent Technologies, Inc. (A), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space